Prostate Cancer (Diagnosis), Prostate Cancer Metastatic, Prostate Cancer Recurrent, Prostate Cancer Stage
Conditions
Keywords
prostate specific membrane antigen(PMSA), prostate cancer, PET/CT
Brief summary
This study aims to use the new molecular probe 18F-PSMA for the diagnosis,staging ,recurrence monitoring and evaluation of the prostate cancer.By compared with the conventional imaging methods (whole body bone scintigraphy and MRI) and molecular imaging methods (11C-choline PET/CT),we hope to find the advantages of 18F-PSMA PET/CT in the diagnosis and metastases of prostate cancer, and lay the foundation for the further clinical transformation.
Detailed description
This study aims to use the new molecular probe 18F-PSMA for the diagnosis,staging ,recurrence monitoring and evaluation of the prostate cancer.By compared with the conventional imaging methods (whole body bone scintigraphy and MRI) and molecular imaging methods (11C-choline PET/CT),we hope to find the advantages of 18F-PSMA PET/CT in the diagnosis and metastases of prostate cancer, and lay the foundation for the further clinical transformation.And make some comparison with those 3 methods.
Interventions
None listed
Sponsors
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Healthy volunteers
No
Inclusion criteria
1. Patients with initial diagnosis of prostate cancer; 1）T2 stage: PSA\>20ng/ml, Gleason Score \>= 8; 2）T3 or T4 stage; 3）The imaging examination was negative or localized metastasis of the pelvic lymph node, but there was no distant metastasis of lymph nodes or bone and internal organs other than the pelvic cavity. 2. Patients with biochemical recurrent prostate cancer; 1）After the RRP surgery, the serum PSA was over 0.2 ng/ml in two consecutive sera; 2）After the radiotherapy: the lowest PSA is up to 2 ng/ml. 3. Patients with CRPC. 1）The serum testosterone is in the castration level (\< 50 ng/dL or \< 1.7 nmol/L); 2）The PSA is elevated 3 times in a row, the base value is increased by more than 50%, and the PSA \> 2ng/mL(the interval is one week); 3）The continuation of the anti-androgen drugs, flunamine was stopped for at least 4 weeks, and biglumide was suspended for at least 6 weeks; 4）Despite the continued standard androgen deprivation therapy, the PSA is still progressing.
Exclusion criteria
1. Patients who are unwilling to participate in the study or unwilling to sign the informed consent forms; 2. Patients who are critically ill, suffering from mental illness and cannot cooperate with the examination; 3. There are electronic implants, such as pacemakers and insulin pumps in the body, and magnetic metal foreign objects in the spot.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 18F-PSMA PET/CT imaging | 4 hours | The outcome of 18F-PSMA PET/CT imaging. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Bone scan imaging | 6 hours | The outcome of bone scan imaging. |
| MRI imaging | 4 hours | The outcome of MRI imaging. |
Countries
China
Contacts
Primary ContactHui Wang, MD
Backup ContactJun Qi, MD
Outcome results
None listed